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In a national register-based study of incidence trends and mortality of incidental prostate cancer in Sweden, we found that a significant
proportion (26.6%) of affected men diagnosed died of their disease, which challenges earlier descriptions of incidental prostate cancer
as a non-lethal disease.
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The clinical significance of incidental prostate cancer (PCa) detected
by transurethral resection (TURP) or by open adenoma enucleation
(OAE) for assumed benign hyperplasia has been a matter of debate
(Epstein et al, 1986; Epstein, 1992; Bostwick, 1995; Adolfsson, 2008).
The main question is whether or not these tumours are biologically
different from other prostate cancers diagnosed by needle biopsy.
Incidental tumours, i.e. tumours found in the specimens of men
undergoing surgery for benign prostatic hyperplasia (BPH), have
been regarded as harmless and have sometimes therefore, been left
without treatment, especially those of small volume (Cantrell et al,
1981). However, recent studies have demonstrated that with
increasing tumour volume (45% of totally resected tissue; T1b
tumours), the clinical course of PCa becomes more unfavourable,
and is comparable to that of palpable T2 tumours (Andren et al,
2006; Cuzick et al,2 0 0 6 ;R o b i n s o net al, 2007). Understanding the
biology of incidental prostate cancer will be increasingly important
as results from biomarker studies based on TURP tissue repositories
become available.
MATERIALS AND METHODS
Using nationwide data from the Swedish National Inpatient
Register, The Swedish Cancer Register and the Cause of Death
Register, linked by national registration number, a unique 10-digit
identification number assigned to all Swedish residents, we
identified all individuals in the Swedish Inpatient Register who
had been discharged after TURP or OAE between 1970 and 2003
(n¼76778). There was almost no private institutional care
available in Sweden during the study period; essentially all men
were referred to and treated at the main hospital in their county of
residence. By record linkage to the essentially complete Cancer
Registry (Mattsson and Wallgren, 1984), we identified all men who
were diagnosed with PCa through TURP or OAE, hereafter referred
to as incidental PCa, which required the following criteria to be
fulfilled: (1) the date of PCa diagnosis had to follow that of first
TURP/OA admission, (2) the date of PCa diagnosis had to be set
within 14 days from discharge, (3) the PCa diagnosis had to be
histopathologically verified, and (4) the hospital stay had to be less
than 60 days. A diagnosis of high-grade intraprostatic neoplasia
was not classified as PCa. In total 23288 men were identified with
incidentally diagnosed PCa. For comparison, we also identified all
men diagnosed with non-incidental PCa in the Swedish Cancer
Register within the same geographical area during the same
period. We excluded all autopsy detected PCa. In total, the study
population including both incidental and non-incidental PCa
comprised 135492 men.
We calculated the age-standardised incidence rates of PCa using
the age distribution of the Swedish population on 1 January 2000,
obtained from Statistics Sweden (Statistiska Centralbyra ˚n (Statis-
tics Sweden), 2008). The men were followed prospectively from
date of cancer diagnosis to death from cancer, or censored from
other causes of death or at end of follow-up (31 December 2003).
We obtained information on cause of death through linkage to the
Cause of Death Registry, and the international classification of
disease (ICD) was used to identify PCa (ICD10¼C619) as the main
cause of death. We calculated cumulative incidence curves to
illustrate the risk of PCa death while accounting for the competing
risk of death from other causes (Kalbfleisch and Prentice, 2002).
All statistical calculations were performed using the statistical
programme package R (Ihaka and Gentleman, 1996).
RESULTS
The characteristics of the study population as well as for all TURP/
OAE procedures undertaken in Sweden between 1970 and 2003 are
presented in Table 1. The age-standardised incidence of incidental
PCa peaked in 1991 at around 37 cases per 100000 men (Figure 1).
Thereafter, it declined successively and reached 12 cases per
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rate of total PCa increased continuously, being almost 15 times
higher at the end of the study period than at the beginning. The
upward trend was initially paralleled by an increased frequency of
TURP, but PCa incidence continued to rise after the incidence of
incidental PCa had levelled off.
We observed a marked decrease in hospitalisation time over
calendar time among men with incidental prostate cancer. In 1970,
when the TURP technique was first introduced, the hospitalisation
time was comparatively long, about 3 weeks (median 24,
interquartile range, 14–33), and after a continuous decrease, it
levelled off at 3 days (median 3, interquartile range, 2–5) in the
most recent period.
Among men with incidental PCa, 6300 died of PCa, 11850 died
of intercurrent causes, and 5138 were still alive at the end
of 2003. The 10-year PCa-specific mortality was 26.6 (95% CI:
26.0–27.2) among men with incidental PCa and 40.7 (95% CI:
40.4–41.0) among men with non-incidental PCa. In the pre-PSA-
era (before 1992), the 10-year PCa-specific mortality was 28.2%
(95% CI: 27.5–28.9) among men with incidental PCa and 46.3%
(95% CI: 45.9–46.8) among men with non-incidental PCa. The
corresponding estimates for the PSA-era (1992 and onwards) were
23.2% (95% CI: 22.2–24.3) among men with incidental PCa and
35.1% (95% CI: 34.6–35.7) among men with non-incidental PCa.
Table 1 Incidental prostate cancer, non-incidental prostate cancer and total number of transurethral resections/open adenoma enucleations
a among men
in Sweden, 1970 and 2003
Incidental prostate cancer Non-incidental prostate cancer TURP or OAE
N % N % N %
Age
o55 123 (0.5) 2462 (2.2) 708 (0.9)
55–64 2157 (9.3) 17740 (15.8) 8931 (11.6)
65–74 9085 (39.0) 43060 (38.4) 30854 (40.2)
75–84 10114 (43.4) 40769 (36.3) 31163 (40.6)
85+ 1809 (7.8) 8173 (7.3) 5122 (6.7)
Years
1970–79 2627 (11.3) 13045 (11.6) 12324 (16.1)
1980–86 6693 (28.7) 17116 (15.3) 20793 (27.1)
1987–90 4961 (21.3) 13311 (11.9) 14409 (18.8)
1991–93 3349 (14.4) 12480 (11.1) 10106 (13.2)
1994–98 2795 (12.0) 20270 (18.1) 9790 (12.8)
1999–2003 2863 (12.3) 35982 (32.1) 9356 (12.2)
Time in hospital
1–3 days 5675 (24.4) NA NA 17929 (23.4)
4–7 days 10997 (47.2) NA NA 34758 (45.3)
8–14 days 4175 (17.9) NA NA 14964 (19.5)
2–4 weeks 1844 (7.9) NA NA 6655 (8.7)
4+ weeks 592 (2.5) NA NA 2423 (3.2)
Procedures (N¼)
a
0 0 (0.0) 82389 (73.4) NA NA
1 18007 (77.3) 23689 (21.1) NA NA
2 4118 (17.7) 4719 (4.2) NA NA
3 864 (3.7) 1062 (0.9) NA NA
4+ 299 (1.3) 345 (0.3) NA NA
Status at end of study
Alive 5138 (22.1) 39527 (35.2) NA NA
Death from other causes 11850 (50.9) 35469 (31.6) NA NA
Death from CaP 6300 (27.1) 37208 (33.2) NA NA
Follow up
Time in years, mean (s.d.) 6.1 (4.7) 4.3 (4.0) NA NA
aOut of 76778 procedures, 4456 (5.8%) were open adenoma enucleations and 72322 transurethral resections of the prostate.
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Figure 1 Age-standardised incidence of TURP-detected and total
prostate cancer in Sweden between 1970 and 2005.
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incidentally detected tumours than among men with non-
incidental PCa, but a considerable number of PCa-specific deaths
occurred in both groups (Figure 2). There was a clear pattern of
decreasing mortality in more recent calendar periods in both
groups, but even in the most recent time period more than 3400
men with incidental PCa died of their disease.
DISCUSSION
In this nationwide, population-based study, we observed dramatic
changes in the incidence of incidental PCa in Sweden over the last
three decades. We found that a significant number of men with
incidental PCa die from their disease. These data do not fit
earlier descriptions of incidental PCa as a non-lethal disease
(Cantrell et al, 1981; Epstein et al, 1986), but lend support to the
hypothesis that incidental PCa have a similar biology to that of
non-incidental PCa.
The introduction of TURP in the late 1970s was accompanied by
an increase in the incidence of prostate cancer (Haapiainen, 1986).
TURP specimens typically represent the transition zone of the
prostate (McNeal et al, 1988a, 1988b), but tumours detected
through TURP may also capture peripheral zone tumours that
have grown into the transition zone (Bostwick, 1995). Tumours
originating in the transition zone have been viewed as low grade
tumours with low potential of malignancy, and men with this type
of tumour have often been treated conservatively (Cantrell et al,
1981; Epstein et al, 1994; Albertsen et al, 2005). Nevertheless,
8–37% of all incidental tumours have been shown to ultimately
progress (Bostwick, 1995). Evidence from a study on radical
prostatectomy patients also indicates that time to biochemical
failure is independent of zonal origin of the tumour (Chun et al,
2007). These data, as well as our finding of a high disease-specific
mortality among men with incidental PCa, support the notion that
incidental and non-incidental PCa may share tumour biology and
potential for progression.
Our data confirm earlier observations of a declining incidence of
incidental tumours after the introduction of PSA screening (Mai
et al, 2000); incidental PCa currently constitutes around 10% of all
diagnosed PCa in Sweden (Regionalt Onkologiskt Centrum ROC,
2003). Our data also demonstrated a decrease in Pca-specific
mortality over time. An increased lead time between diagnosis and
death after the introduction of the PSA test as well as potentially
improved treatments seem more likely to explain this observation
than a gradual shift in tumour biology/aggressiveness.
This large, register-based study with an essentially complete
follow-up allowed a comprehensive examination of incidence
and mortality trends in Sweden over the last three decades. As
health care is free to all Swedish residents, selection forces
associated with the TURP procedure should be minimal. A
limitation, shared by all register-based studies, though, is the
quality of available data. The accuracy of the official causes of
death data, with regard to prostate cancer, should however be
adequate (Fall et al, 2008).
These data demonstrated that a significant proportion of men
with incidental prostate cancer during the last three decades died
from their disease. Findings from biomarker studies that utilise
archival tissue specimens from such incidental cases (for predic-
tion of PCa outcomes) may thus contribute to the understanding of
the natural course of prostate cancers detected today.
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